相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial
Juan P. Frias et al.
DIABETES OBESITY & METABOLISM (2017)
Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk
DIABETES CARE (2016)
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
Michael Nauck et al.
DIABETES CARE (2016)
Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes
Jessica E. Matthews et al.
POSTGRADUATE MEDICINE (2016)
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
Qing Qiao et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2016)
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
Rimei Nishimura et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
Francesco Giorgino et al.
DIABETES CARE (2015)
AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2015
Alan J. Garber et al.
ENDOCRINE PRACTICE (2015)
Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
Marcus Lind et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
Marcus Lind et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
Stephen S. Johnston et al.
ADVANCES IN THERAPY (2014)
Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function
Ling Hinshaw et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus
Yutaka Seino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias
Annett Stahn et al.
DIABETES CARE (2014)
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaela Diamant et al.
DIABETES CARE (2014)
Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials
B. Ahren et al.
DIABETES OBESITY & METABOLISM (2014)
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes
J. Farngren et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2014)
Guideline for management of postmeal glucose in diabetes
Antonio Ceriello et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
Julio Rosenstock et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Failure to Reach Target Glycated A1c Levels Among Patients with Diabetes Who Are Adherent to Their Antidiabetic Medication
Deborah Taira Juarez et al.
POPULATION HEALTH MANAGEMENT (2014)
The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c
Feng Xu et al.
DIABETOLOGY & METABOLIC SYNDROME (2014)
Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: An observational study
Sanjay Chatterjee et al.
JOURNAL OF DIABETES (2014)
Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes
Bernard Peene et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2014)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
R. Balena et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent-Naive Subjects with Type 2 Diabetes
Jian Zhou et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2013)
A review of the efficacy and safety of oral antidiabetic drugs
Stephanie Aleskow Stein et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Achievement of Goals in U.S. Diabetes Care, 1999-2010
Mohammed K. Ali et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
Linong Ji et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca et al.
DIABETES CARE (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2012)
Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage
V. Fonseca et al.
DIABETES OBESITY & METABOLISM (2012)
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
T. Ridge et al.
DIABETES OBESITY & METABOLISM (2012)
Add-On Therapies to Metformin in Type 2 Diabetes: What Modulates the Respective Decrements in Postprandial and Basal Glucose?
Louis Monnier et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes
Gong Su et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Therapy in the Early Stage: Incretins
Simona Cernea et al.
DIABETES CARE (2011)
DPP-4 Inhibitors Impact on glycemic control and cardiovascular risk factors
Dror Dicker
DIABETES CARE (2011)
Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up
Franco Cavalot et al.
DIABETES CARE (2011)
Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Matthew Riddle et al.
DIABETES CARE (2011)
Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis
A. E. Pontiroli et al.
DIABETES OBESITY & METABOLISM (2011)
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
T. Forst et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
P. Barrington et al.
DIABETES OBESITY & METABOLISM (2011)
Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes
Mi K. Kim et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Postprandial hyperglycemia is highly prevalent throughout the day in type 2 diabetes patients
Jan-Willem van Dijk et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Encapsulation of Exenatide in Poly-(D,L-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
Mary Beth DeYoung et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes
Thomas Blevins
POSTGRADUATE MEDICINE (2011)
Saxagliptin and met formin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with met formin
Kaj Stenlof et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
Matthew Riddle et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Incretin-Based Therapies Viewpoints on the way to consensus
Michael A. Nauck et al.
DIABETES CARE (2009)
Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial
Tali Cukierman-Yaffe et al.
DIABETES CARE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes
Robert G. Brodows et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
Ralph A. DeFronzo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients
Antonio Ceriello et al.
DIABETES (2008)
Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes
C. Gredal et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients
Hiroyuki Shimizu et al.
ENDOCRINE JOURNAL (2008)
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Jessica E. Matthews et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Insulin-associated weight gain in diabetes - causes, effects and coping strategies
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2007)
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin
Matthew Riddle et al.
DIABETES CARE (2007)
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes
Gerrard Rayman et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight
Diane Karl et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2007)
Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes:: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors
Antonio Ceriello et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2007)
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic Hyperglycemia in patients with type 2 diabetes
L Monnier et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
I Chapman et al.
DIABETOLOGIA (2005)
alpha-Glucosidase inhibitors for patients with type 2 diabetes - Results from a cochrane systematic review and meta-analysis
FA van de Laar et al.
DIABETES CARE (2005)
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Z Arvanitakis et al.
ARCHIVES OF NEUROLOGY (2004)
Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin
T Nakagami
DIABETOLOGIA (2004)
A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes
AH Barnett et al.
DIABETES OBESITY & METABOLISM (2004)
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes
MS Fineman et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study
DG Maggs et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes
RG Bretzel et al.
DIABETES CARE (2004)
Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes
JS Christiansen et al.
DIABETES OBESITY & METABOLISM (2003)
Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions
H Schatz et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2003)
Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus:: A multicenter, multinational, non-randomized, non-controlled Latin American study
S Islas-Andrade et al.
PHARMACOLOGY (2003)
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients -: Variations with increasing levels of HbA1c
L Monnier et al.
DIABETES CARE (2003)
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes - A dose-timing study
C Weyer et al.
DIABETES CARE (2003)
Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes
J Vakkilainen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans - Role of oxidative stress
K Esposito et al.
CIRCULATION (2002)
The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus
M Fineman et al.
HORMONE AND METABOLIC RESEARCH (2002)
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
F Whitehouse et al.
DIABETES CARE (2002)
Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion
Y Uto et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes
M Hanefeld et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2002)
Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes -: Implications for treatment and monitoring of metabolic control
E Bonora et al.
DIABETES CARE (2001)
Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes
LF Van Gaal et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2001)
Importance of early insulin secretion - Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes
PA Hollander et al.
DIABETES CARE (2001)
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes
JL Chiasson et al.
DIABETES CARE (2001)
Meglitinide analogues in the treatment of type 2 diabetes mellitus
R Landgraf
DRUGS & AGING (2000)
分享论文
